Yes, Benlysta (belimumab) is a biologic. It was the first biologic drug approved for the treatment of systemic lupus erythematosus (SLE), receiving FDA approval in 2011. Specifically, it is a fully human monoclonal antibody, meaning it was engineered from human immune proteins rather than synthesized chemically like traditional medications.
What Makes Benlysta a Biologic
Biologics are a class of drugs made from living cells rather than chemical compounds. Unlike conventional medications that are manufactured through chemical reactions in a lab, biologics are produced using biological systems, typically genetically modified cells grown in controlled environments. This makes them large, complex molecules that can’t be replicated exactly the way a generic pill can.
Benlysta fits squarely in this category. It is a monoclonal antibody, which is one of the most common types of biologic drugs. Monoclonal antibodies are lab-made proteins designed to target one very specific substance in the body. In Benlysta’s case, the target is a protein called B-lymphocyte stimulator (BLyS), sometimes also referred to as BAFF. This protein normally helps B cells (a type of immune cell) survive and multiply. In lupus, the immune system is overactive, and BLyS levels tend to be elevated. Benlysta binds to BLyS and blocks it, which reduces the number of problematic B cells and helps dial down the autoimmune attack.
What Benlysta Is Approved to Treat
Benlysta is indicated as an add-on to standard therapy for adults and children (age 5 and older) with active, autoantibody-positive systemic lupus erythematosus. It was also approved in 2020 for lupus nephritis, a serious form of kidney inflammation caused by lupus. In both cases, it is used alongside other lupus medications, not as a standalone treatment.
The “autoantibody-positive” requirement is important. Your blood tests need to show that your immune system is producing antibodies against your own tissues. This confirms the type of immune activity that Benlysta is designed to reduce. Not every lupus patient will meet this criterion.
How It Is Given
Benlysta comes in two forms: an intravenous (IV) infusion given at a clinic and a subcutaneous injection you can give yourself at home.
The IV version is administered over about one hour. Treatments start every two weeks for the first three doses, then shift to once every four weeks. This option requires regular visits to an infusion center.
The subcutaneous version is a prefilled syringe or autoinjector administered in the abdomen or thigh. For active lupus, the standard adult dose is 200 mg once weekly. For lupus nephritis, treatment starts at a higher loading dose of 400 mg weekly for the first four weeks, then drops to 200 mg weekly. Children weighing under 40 kg follow adjusted schedules with longer intervals between doses. Many patients prefer the at-home injection because it eliminates the time commitment of infusion visits, though both forms deliver the same drug.
How Benlysta Compares to the Only Other Lupus Biologic
For over a decade, Benlysta was the sole biologic available for lupus. That changed in 2021 when the FDA approved anifrolumab (Saphnelo), a second biologic for moderate to severe active SLE. These two drugs work through completely different pathways. While Benlysta blocks BLyS to reduce B cell activity, Saphnelo targets a receptor involved in the type I interferon response, a separate branch of immune signaling that drives inflammation in many lupus patients.
Because they hit different molecular targets, the two drugs have distinct side effect profiles and may suit different patients depending on which immune pathways are most active in their disease. Having two biologics with different mechanisms gives rheumatologists more flexibility when standard treatments aren’t controlling symptoms well enough.
Side Effects and Safety
Because Benlysta suppresses part of the immune system, infections are the primary concern. Your body’s ability to fight off certain infections is reduced while on the drug, so staying current on vaccinations (using non-live vaccines) before starting treatment is recommended.
Early in Benlysta’s history, there were concerns about psychiatric side effects, including depression and suicidal thoughts. A large meta-analysis of randomized controlled trials found no statistically significant increase in psychiatric disorders, serious psychiatric events, suicidal ideation, or depression compared to placebo across all tested doses. However, one large post-approval safety study did suggest a possible increase in psychiatric adverse events with belimumab exposure, so mood changes are still something to be aware of.
Infusion reactions can occur with the IV form, including fever, nausea, and skin reactions. These are most common during the first two infusions and tend to become less frequent over time. The subcutaneous form can cause injection site reactions like redness or swelling, which are typically mild.
What to Expect if You Start Treatment
Benlysta is not a fast-acting drug. Because it works by gradually reducing the population of overactive B cells, it can take several months before you notice meaningful improvement in your symptoms. Clinical trials measured outcomes over 52 weeks, and benefits tend to build over time. This is common with biologics that modify the immune system rather than simply suppressing inflammation.
You will continue taking your other lupus medications alongside Benlysta. It is designed to be layered on top of standard therapy, which typically includes antimalarials like hydroxychloroquine, along with immunosuppressants and sometimes corticosteroids. The goal is usually to get lupus activity under enough control that steroid doses can be reduced over time, since long-term steroid use carries its own serious risks.
For lupus nephritis specifically, Benlysta is started within 60 days of beginning induction therapy (the intensive first phase of treatment). Patients who have already achieved a complete kidney response on standard therapy alone are unlikely to get significant additional benefit from adding Benlysta.